Metabolic Reprogramming in Thyroid Cancer
Endocrinology and Metabolism · 30.06.2024 · 39 (3) · 425-444
DOI: 10.3803/enm.2023.1802 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Endocrinology and Metabolism, erschienen am 30.06.2024. Verfasst von Sang-Hyeon Ju und 5 weiteren Autor:innen. Beteiligte Einrichtung: Division of Endocrinology and Metabolism, Department of Internal Medicine, Chungnam National University Hospital, Daejeon, Korea. Hauptthemen laut MEDLINE: Thyroid Neoplasms. Die Arbeit wurde bisher 36-mal zitiert (Crossref) und nennt 160 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Chungnam National University.
Abstract (Originalsprache)
Thyroid cancer is a common endocrine malignancy with increasing incidence globally. Although most cases can be treated effectively, some cases are more aggressive and have a higher risk of mortality. Inhibiting RET and BRAF kinases has emerged as a potential therapeutic strategy for the treatment of thyroid cancer, particularly in cases of advanced or aggressive disease. However, the development of resistance mechanisms may limit the efficacy of these kinase inhibitors. Therefore, developing precise strategies to target thyroid cancer cell metabolism and overcome resistance is a critical area of research for advancing thyroid cancer treatment. In the field of cancer therapeutics, researchers have explored combinatorial strategies involving dual metabolic inhibition and metabolic inhibitors in combination with targeted therapy, chemotherapy, and immunotherapy to overcome the challenge of metabolic plasticity. This review highlights the need for new therapeutic approaches for thyroid cancer and discusses promising metabolic inhibitors targeting thyroid cancer. It also discusses the challenges posed by metabolic plasticity in the development of effective strategies for targeting cancer cell metabolism and explores the potential advantages of combined metabolic targeting.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Endocrinology and Metabolism, Department of Internal Medicine, Chungnam National University Hospital, Daejeon, Korea.
- Department of Internal Medicine, Chungnam National University College of Medicine, Daejeon, Korea.
- Graduate School of Medical Science and Engineering, Korea Advanced Institute of Science and Technology, Daejeon, Korea.
Förderung
- Chungnam National University
Zitieren
APA
Ju, S. H., Song, M., Lim, J. Y., Kang, Y. E., Yi, H. S., & Shong, M. (2024). Metabolic Reprogramming in Thyroid Cancer. Endocrinology and Metabolism, 39(3), 425-444. https://doi.org/10.3803/enm.2023.1802
Vancouver
Ju SH, Song M, Lim JY, Kang YE, Yi HS, Shong M. Metabolic Reprogramming in Thyroid Cancer. Endocrinology and Metabolism. 2024;39(3):425-444. doi:10.3803/enm.2023.1802
BibTeX
@article{Ju2024,
author = {Ju, Sang-Hyeon and Song, Minchul and Lim, Joung Youl and Kang, Yea Eun and Yi, Hyon-Seung and Shong, Minho},
title = {Metabolic Reprogramming in Thyroid Cancer},
journal = {Endocrinology and Metabolism},
year = {2024},
volume = {39},
number = {3},
pages = {425--444},
doi = {10.3803/enm.2023.1802}
}
EUVIMED